Systematic Review of Nasal Endoscopy Scores in Cystic Fibrosis Patients Treated With Cystic Fibrosis Transmembrane Conductance Regulator Modulators
Pediatric Pulmonology · 2026-04 · 61 (4)
DOI: 10.1002/ppul.71601 ↗At a glance
Systematische Übersicht in Pediatric Pulmonology, published online on 2026-04-01. Written by Rebecca Gallardo and 4 co-authors. Institution: Departamento de Otorrinolaringologia e Cirurgia de Cabeça e Pescoço, Universidade Estadual de Campinas (UNICAMP), Campinas, São Paulo, Brasil. Major MEDLINE topics: Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator, Rhinosinusitis, Nasal Polyps. Cited 2 times so far (Crossref); 28 references. The full text is freely available (open access, CC BY 4.0). Funded by: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brasil (CAPES) (ROR identifier: 00x0ma614).
Abstract (original language)
Introduction
Cystic fibrosis (CF) is a severe genetic disorder caused by pathogenic variants in the Cystic Fibrosis Transmembrane Conductance Regulator ( CFTR ) gene, leading to multisystem complications including chronic rhinosinusitis and nasal polyposis. Recent advances in CFTR modulator therapies have revolutionized systemic disease control, but their impact on sinonasal disease remains less explored.
Methods
A systematic review was conducted following Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) guidelines and registered in International Prospective Register of Systematic Reviews (PROSPERO, registration number CRD42025632498). Searches were performed across PubMed/MEDLINE, Cochrane Library, and Embase through March 2025. Studies reporting nasal endoscopic outcomes using validated scoring systems before and after CFTR modulator therapy were included.
Results
Out of 232 identified records, 10 studies met inclusion criteria, representing populations from six countries. Most studies assessed triple therapy (Elexacaftor/Tezacaftor/Ivacaftor). Endoscopic scores, including the Modified Lund‐Kennedy scale, showed significant reductions in nasal polyps, mucosal edema, and discharge. Pediatric and adult groups benefited alike, with triple therapy proving more effective than dual or monotherapy. Secondary outcomes included improved pulmonary function, weight gain, and olfactory recovery.
Conclusion
This review demonstrates that CFTR modulators provide significant benefits for sinonasal disease in CF, reinforcing their role as a comprehensive therapeutic approach addressing both upper airway and systemic disease burdens.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Departamento de Otorrinolaringologia e Cirurgia de Cabeça e Pescoço, Universidade Estadual de Campinas (UNICAMP), Campinas, São Paulo, Brasil.
- University of Taubaté (UNITAU), Caraguatatuba, São Paulo, Brazil.
- Departamento de Pediatria, Universidade Estadual de Campinas (UNICAMP), Campinas, São Paulo, Brasil.
ORCID profiles: Rebecca Gallardo, Bruna Santos Silva, Lucas Sousa Salgado, José Dirceu Ribeiro, Eulalia Sakano
Funding
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brasil (CAPES) (ROR identifier: 00x0ma614)
Cite
APA
Gallardo, R., Silva, B. S., Salgado, L. S., Ribeiro, J. D., & Sakano, E. (2026). Systematic Review of Nasal Endoscopy Scores in Cystic Fibrosis Patients Treated With Cystic Fibrosis Transmembrane Conductance Regulator Modulators. Pediatric Pulmonology, 61(4). https://doi.org/10.1002/ppul.71601
Vancouver
Gallardo R, Silva BS, Salgado LS, Ribeiro JD, Sakano E. Systematic Review of Nasal Endoscopy Scores in Cystic Fibrosis Patients Treated With Cystic Fibrosis Transmembrane Conductance Regulator Modulators. Pediatric Pulmonology. 2026;61(4). doi:10.1002/ppul.71601
BibTeX
@article{Gallardo2026,
author = {Gallardo, Rebecca and Silva, Bruna Santos and Salgado, Lucas Sousa and Ribeiro, José Dirceu and Sakano, Eulalia},
title = {Systematic Review of Nasal Endoscopy Scores in Cystic Fibrosis Patients Treated With Cystic Fibrosis Transmembrane Conductance Regulator Modulators},
journal = {Pediatric Pulmonology},
year = {2026},
volume = {61},
number = {4},
doi = {10.1002/ppul.71601}
}
EUVIMED